Related Experiment Video

Updated: Feb 15, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K

Post-exposure treatments for Ebola and Marburg virus infections

Robert W Cross1,2, Chad E Mire1,2, Heinz Feldmann3

  • 1Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas 77555, USA.

Nature Reviews. Drug Discovery
|January 30, 2018
PubMed

Insights

Ebola and Marburg virus hemorrhagic fevers pose significant threats. Recent Ebola therapies effective in animal models failed in human patients, highlighting the need for improved medical countermeasures.

Area of Science:

  • Virology
  • Infectious Diseases
  • Public Health

Background:

  • Filoviruses, including Ebola virus and Marburg virus, cause severe hemorrhagic fevers in humans and non-human primates (NHPs).
  • These viruses represent a substantial global health risk due to natural outbreaks and potential bioterrorism applications.
  • Previous promising post-exposure therapies, effective in NHP models, did not achieve statistically significant protection during the 2013-2016 Ebola outbreak.

Purpose of the Study:

  • To discuss the failures of recent Ebola therapies in human patients.
  • To review lessons learned from these therapeutic setbacks.
  • To summarize the current landscape of developing post-exposure medical countermeasures against filoviruses.

Main Methods:

  • Review of scientific literature and clinical trial data related to filovirus therapies.
  • Analysis of efficacy data from NHP models versus human patient outcomes.
  • Synthesis of information on ongoing development of antibodies, small interfering RNA (siRNA), and small molecule therapeutics.

Main Results:

  • Therapies successful in NHP models for filovirus disease did not demonstrate statistically significant protection in human Ebola patients.
  • Significant knowledge gaps and challenges exist in translating preclinical findings to clinical success.
  • Several classes of medical countermeasures, including antibodies, siRNA, and small molecules, are under active development.

Conclusions:

  • Past therapeutic failures provide critical insights for future research and development.
  • Improved strategies are needed for identifying and effectively deploying novel filovirus interventions.
  • Further research is essential to develop robust and clinically validated post-exposure treatments for filovirus infections.

More Related Videos

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

9.2K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.4K

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
128.5K
Post-traumatic Stress Disorder01:27

Post-traumatic Stress Disorder

Post-traumatic stress disorder (PTSD) is a psychiatric condition that arises following exposure to traumatic events such as natural disasters, forced displacement, or severe accidents. It significantly impairs individuals' ability to cope with daily activities and disrupts their emotional and psychological equilibrium.
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
595
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
19
Infection01:20

Infection

When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
12.8K
Introduction to Virus01:28

Introduction to Virus

Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
1.9K
Viruses of Archaea01:29

Viruses of Archaea

Archaeal viruses play a crucial role in the ecosystems of extremophilic archaea, particularly those belonging to the phyla Euryarchaeota and Crenarchaeota. By shaping host evolution and facilitating gene transfer, these viruses influence microbial communities and contribute to genetic diversity in extreme environments. The archaea they infect thrive in acidic hot springs and hydrothermal vents characterized by high temperatures and low pH. Archaeal viruses exhibit remarkable structural...
534